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HematopoiesisMicroRNAs (miRNAs) are small, noncoding RNAs of 18–22 nucleotides in length that regulate post-
transcriptional expression by base-pairing with target mRNAs. It is now clearly established that miRNAs are
involved in most of the cell's physiopathological processes (including carcinogenesis and metabolic disorders).
This review focuses on miR-223, which was ﬁrst described as a modulator of hematopoietic lineage differentia-
tion.Weoutline the role ofmiR-223 deregulation in several types of cancers and highlight its inclusion in a newly
identiﬁed and fast-growing family of miRNAs called oncomiRs. We then look at miR-223's emerging role in
inﬂammatory andmetabolic disorders, with a particular focus onmuscle diseases, type II diabetes, atherosclerosis
and vascular calciﬁcation. miR-223 is one of the growing number of RNA biomarkers of various humanmetabolic
diseases and is thus of special interest to both researchers and clinicians in the cardiovascular ﬁeld.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are small, non-coding, regulatory RNAs that
range from 18 to 22 nucleotides (nt) in length. They aremainly encoded
by gene introns but are also sometimes encoded by dedicated genes.
ThemiRNAs regulate the expression of speciﬁc target proteins by either
inhibiting translation or degrading the correspondingmRNA. It has beenAcuteMyeloid Leukemia; Apo-E
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etzinger).estimated that miRNAs regulate between one and two thirds of the
human genome [1] and are involved in most of the cell's main functions
(including growth, proliferation, differentiation, signal transduction, apo-
ptosis, metabolism and aging) [2]. At present, the majority of researchers
consider that miRNAs act predominantly by inhibiting the translation
of their target mRNAs, rather than by inducing degradation. However,
Bartel's group has shown that mammalian miRNAs degrade their target
mRNAs in most cases and thus decrease protein levels [8]. Regardless of
the exact mechanism, miRNAs are posttranscriptional regulators that
bind to their target mRNAs (mostly to the 3′ untranslated region (UTR)
but sometimes within the coding region or the 5′ UTR) [1–3].
Many studies have demonstrated thatmiRNA expression is correlated
with disease (ﬁrst in cancer [4] and then in cardiovascular disease [5]).
The miRNAmiR-223 has a key role in the development and homeostasis
of the immune system. To date, miR-223's involvement has been demon-
strated for many types of cancers, inﬂammatory diseases, autoimmune
diseases and other pathological processes. The present article reviews
our current knowledge of the physiopathology of miR-223 microRNA
(starting with the pioneering work in cancer and inﬂammation) and
then focuses on this miRNA's emerging role in the cardiovascular ﬁeld.
2. miR-223 biological functions
2.1. Location of the gene encoding miR-223 and regulation of its promoter
The fact that the sequence of miR-223 has been remarkably con-
served during evolution suggests that this mRNA has an important
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located within the q12 locus of the X chromosome (Fig. 1B) [6]. It was
discovered in silico [7] and then detected in a hematopoietic system
[8]. Expression of the miR-223 is regulated by several transcription
factors, including transcription factor PU.1, CCAAT-enhancer-binding
proteins (C/EBP)-α and -ß and nuclear factor I-A (NFI-A) (Fig. 1C).
More precisely, PU.1 is involved in osteoclast differentiation and binds
to two separate sites within the miR-223 promoter region. Expression
of PU.1 is induced by macrophage colony stimulating factor (MCSF)
and the receptor activator of nuclear factor kappa-B ligand (RANKL). It
has been shown that PU.1 binds to the miR-223 promoter to activate
expression of the miRNA, which in turn induces osteoclastogenesis by
targeting osteoclast-speciﬁc target mRNAs [8,9]. Similarly, C/EBP-α
binds to the miR-223 promoter, which increases miR-223 expression
and, as a result, promotes granulocyte differentiation [10]. In contrast,
NFI-A binds to the promoter of themiR-223 gene, inhibits its expression
and thus decreases granulocyte and osteoclast differentiation [8–10]. It is
noteworthy thatmiR-223 also targets NFI-A— thus producing a negative
feedback loop between the target gene and its corresponding miRNA
[10]. During this regulation, miR-223 is translocated into the nucleus,
where it binds to and silences the NFI-A promoter. As with miR-223,
the (complimentary) sequence of the NFI-A promoter has been highly
conserved during evolution (Fig. 2) [11]. The same researchers demon-
strated that miR-223 is also able to suppress expression of the NFI-A
gene via heterochromatin repression. The biogenesis of miR-223, with
its regulation by NFI-A, is comprehensibly described in Fig. 2.
A pioneering study demonstrated the existence of semi-microRNAs;
these are 12 nt in length and correspond to the 5′ or 3′ half of themature
miRNA. The semi-miRNAs are produced during miRNA maturation [12]
and are devoid of any direct regulation effects on the corresponding
miRNA's target mRNA. The semi-miRNA derived from miR-223 (smiR-
223) nevertheless modulates miR-223's ability to repress translation or
degradation of target transcripts and thus controls indirectly gene
expression [12].
2.2. Physiological function
The ﬁrst important role of miR-223 was discovered in the ﬁeld of
hematology, since it was shown to modulate the differentiation ofFig. 1. A. Sequence alignment of themature miR-223, showing its remarkable conservation dur
representation of the transcription factor network that regulates the expression of miR-223. Rehematopoietic lineages [7]. This function takes place in the hematopoi-
etic bone marrow and affects hematopoietic stem cells and myeloid,
erythroid and lymphoid cells at various stages of their development
[7]. In the bone marrow, miR-223 expression is mainly conﬁned to my-
eloid cells and is induced during the lineage differentiation of myeloid
progenitor cells. These myeloid cells will differentiate in monocyte/
macrophage and granulocyte cells. Expression of miR-223 is highly
lineage-speciﬁc, since it is repressed when granulocyte–monocyte pro-
genitors start to differentiate into monocytes. Conversely, miR-223 is
highly expressed when granulocyte–monocyte progenitors enter the
granulocyte differentiation phase [7]. In contrast, the same researchers
developed miR-223−/−mice and showed that miR-223 is not strictly
essential for granulocyte differentiation butwas required for normalmat-
uration of granulocytes and regulation of the granulocyte compartment
size. The researchers observed marked neutrophilia and hyperplasia of
the bone marrow granulocyte compartment in these miR-223−/−
mice. Another study demonstrated that miR-223−/−mice suffer from
lung inﬂammatory damage anddisplay tissue destruction after endotoxin
treatment [13].
miR-223 has also a role in monocyte/macrophage differentiation,
since it targets and represses IκB kinase subunit alpha (IKK-α), a compo-
nent of nuclear factor-kappa B (NF-κB) pathway. Duringmacrophage dif-
ferentiation, a fall in miR-223 expression induces an increase of IKK-α
expression which induces the expression of p52 followed by the repres-
sion of NF-κB pathways [13,14] (Table 1). miR-223-richmicrovesicles in-
duce the differentiation of recipient monocytes, activate hematopoietic
cell production in the bone marrow and then induce the release of
more microvesicles [15]. Aucher et al. [16] have demonstrated that
miR-223 transfer from human macrophages to hepato-carcinoma cells
and inhibit their proliferation. In this elegant paper, they demonstrated
that miR-223 expression cells increased in HuH7 transformed hepatic
cells after co-incubation with macrophages. However, this increase was
prevented by chemical ﬁxation of macrophages. In this experience, sur-
face proteins still interacted with other cells but dynamic processes,
such as secretion, were inhibited. Using several inhibitors of gap junction
activity, they further demonstrated that endogenousmacrophages trans-
fer miRNA to HuH7 cells in a process dependent on cell–cell contacts and
gap junction. Yuan et al. [17] studied the erythroid–megakaryocyte cell
line K562 and found that miR-223 was downregulated during erythroiding the evolution. B. The genomic location of miR-223 on the X chromosome. C. A pictorial
levance in granulopoiesis, monocyte/macrophage differentiation and osteoclastogenesis.
Fig. 2. Schematic representation of miR-223 biogenesis and regulation. Various transcription factors (such as PU.1 and NFIA) bind themiR-223 promoter and activate transcription of the
gene encoding miR-223. MiR-223 is transcribed as a single pri-miRNA. The Drosha and DiGeorge Syndrome Critical Region 8 (DGCR8) complex processes the pri-miRNA into a hairpin-
structured pre-miRNA. The pre-miRNA corresponding tomiR-223 is exported by a nucleocytoplasmic shuttle protein (exportin) from the nucleus to the cytoplasm and is then cleaved by
the Dicer complex into a miRNA duplex. Lastly, the miRNA duplex is unwound to obtain the mature miR-223, which is incorporated into the RNA-induced silencing complex (RISC) and
binds variousmRNA targets in their 3′ UTR. miR-223 targets the NFIA transcript in the cytoplasm but also acts in the nucleus by inhibiting the production of NFIA, which in turn decreases
the production of miR-223 in a feedback loop.
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fact, miR-223 targets and regulates the expression of the LIM domain
only 2 (rhombotin-like 1) (LMO2) transcription factor, a bridging mole-
cule that serves to assemble an erythroidDNA-binding complex including
GATA-binding factor 1 (GATA-1) [17] (Table 1). During erythroid
differentiation, LMO2 levels increase as miR-223 levels decrease, which
promotes the differentiation of K562 cells into erythrocytes.
miR-223 also has an important role in osteoclast formation and the
regulation of bone remodeling. Indeed, the miRNA is expressed in oste-
oclast precursors (RAW 264.7 cells); both under- and over-expression
of miR-223 expression diminish the osteoclast-like cell formation
induced by RANKL [9]. This indicates that the expression of miR-223
must be ﬁne-tuned for normal osteoclastogenesis. NFI-A is involved inTable 1
Targets of miR-223 known to be involved in physiopathological processes.
miR-223
Function Target(s)
Osteoclastogenesis NF-IA
Granulopoiesis IKKα
NF-IA
E2F1
Erythropoiesis LMO2
Cell invasiveness MEF2C
Tumor suppressor EPB4IL3
Tumorigenesis STMN1, FBW7
KRAS,EGF,EGFR2, MMP9, SEPTIN6
Inﬂammation NLRP3
Pknox1
Glucose uptake GLUT-4
VSMC proliferation IGF-1R
VSMC contractile phenotype Rho B, MEF2Cthis process too, since it suppresses osteoclastogenesis. In fact, NFI-A
inhibits the expression of the MCSF receptor, which in turn is essential
for osteoclast differentiation, function and survival [10,18,9] (Table 1).
miR-223 was recently demonstrated to regulate human embryonic
stem cell (hESC) differentiation by targeting the IGF-1R/Akt signaling
pathway [19]. The inhibition of miR-223 expression maintained hESCs
in the undifferentiated state, while addition of exogenous miR-223
induced their differentiation. These effects were dependent of the IGF-
1R/Akt pathway, since IGF-1R mRNA was demonstrated to be a target
of miR-223. The level of phosphorylated Akt, a downstream kinase of
the IGF-1R signaling pathway was higher in cells where miR-223 was
depleted than in those expressing exogenous levels of miR-223
(Table 1).Clinical relevance References
Vascular calciﬁcation? [8–10]
? [13,14]
? [8–10]
Leukemia [21]
[17]
Breast cancer [22]
Gastric cancer [24]
Hepatocellular carcinoma, gastric cancer [25,26]
Ovarian cancer [28]
IL-1ß production? [29]
Anti-inﬂammatory response [30]
Diabetes, heart failure [37]
Vascular stretch stress (essential hypertension?) [41]
Vascular calciﬁcation [43]
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regulated during hematopoiesis by a number of transcription factors
including PU.1, C/EBP-α and -ß, andNFI-A.miR-223modulates the differ-
entiation of the hematopoietic lineage and is conﬁned in myeloid cells. It
is repressed when granulocyte–monocyte progenitors start to differenti-
ate intomonocytes and is highly expressedwhen granulocyte–monocyte
progenitors enter the granulocyte differentiation phase. Its expression
is also required for megakaryocyte differentiation. In addition to the he-
matopoietic differentiation, miR-223 also regulates osteoclastogenesis,
and the differentiation of human embryonic stem cells.
3. miR-223 is involved in the carcinogenesis process
miR-223 expression is deregulated in many types of cancer; miR-223
is thus a member of an emerging family of miRNAs called oncomiRs.
3.1. Leukemia
miR-223 is poorly expressed in acute myeloid leukemia [20] (AML)
and several other types of leukemia. Eyholzer et al. found a low level
of miR-223 in AML and demonstrated that this could not be attributed
to mutation and/or hypermethylation of miR-223 gene regulatory
elements (i.e. the NFI-A, CEBP and PU.1 binding sites; Table 1). The re-
searchers concluded that miR-223 suppression in AML patients was
probably due to the deregulation of transcription factors and/ormiRNAs
upstream of miR-223. Another study has demonstrated that miR-223
targets E2F1, a regulator of the cell cycle during granulopoiesis [21].
However, miR-223 is downregulated in several subtypes of leukemia,
which in turn induces an increase in E2F1 and thus the risk of carcino-
genesis. Furthermore, the same researchers demonstrated that E2F1
binds to the miR-223 promoter in AML cells and thus worsens the
phenomenon by inhibiting transcription of miR-223.
3.2. Breast cancer
miR-223 was found to promote breast cancer invasiveness [22].
Indeed, tumor-associated macrophages induced by interleukin-4 (IL-4)
promote breast cancer invasion and metastasis through macrophage-
secreted exosomes that deliver miR-223 to breast tumor cells. The
researchers also showed that the invading power of the co-cultivated
breast cancer cells faded when miR-223 expression in IL-4-activated
macrophages was decreased by treatment withmiR-223 antisense oligo-
nucleotide. Myocyte enhancer factor 2c (Mef2c, a target of miR-223)
is instrumental in promoting breast cancer invasiveness through the
Mef2c–ß-catenin pathway (Table 1). Furthermore, Mef2c targeting by
miR-223 has been shown to inhibit proliferation and granulocyte func-
tion in myeloid progenitor cells [7].
3.3. Gastric cancer
Li et al. [23] examinedmiRNAs in several humangastric cell lines and
showed that miR-223 is speciﬁcally overexpressed in metastatic gastric
cells, stimulating migration and invasion. Indeed, Li et al. demonstrated
that expression of miR-223 (induced here by the transcription factor
Twist) downregulates that of erythrocyte membrane protein band
4.1-like 3 (EPB41L3) [24] by directly targeting its 3′-UTR. Interestingly,
EPB41L3 is believed to link membrane receptors to the cytoskeleton
and display tumor-suppressive capabilities and its expression is progres-
sively lost in gastric cancers. Another study [25] demonstrated that
the oncogenic cytosolic microtubule-destabilizing protein stathmin1/
oncoprotein 18 (STMN1) is targeted by miR-223 in gastric cancer. In
both gastric cancer cell lines and primary gastric adenocarcinoma cells,
upregulation of STMN1 promotes cell proliferation, invasion and migra-
tion (Table 1). The researchers also showed that miR-223 was down-
regulated in several cancer gastric cell lines, so miR-223 speciﬁcally
targets STMN1 expression. miR-223 expression is also upregulated ingastric cancer tissue samples [26]. This study clearly showed that levels
of miR-223 and a combination of six other miRNAs formed a powerful
biosignature for the prediction of overall survival and disease-free
survival in gastric cancer patients. Furthermore, transfection of miR-223
into the SGC7901 gastric cancer cell line induced a reduction in apoptosis
and a concomitant increase in in vitro proliferation and invasion. Similar
results were found in tumorigenesis assays performed in nude mice. A
molecular explanation was found when miR-223 was shown to target
FBW7, which has a role in the ubiquitin-dependent proteolysis of several
oncoproteins [26].
3.4. Hepatocellular carcinoma
Expression of miR-223 is repressed in hepatocellular carcinoma
(HCC) in chronic carriers of hepatitis B virus and hepatitis C virus and
in nonviral-associated patients [27]. Conversely, the transfection of ei-
ther precursor or mature miR-223 into the corresponding HCC cell
lines reduced the cancer cells' viability. Similarly, STMN1 was found to
be over-expressed in HCC. A strong inverse correlation between
STMN1 mRNA expression and miR-223 levels was demonstrated.
STMN1 has a functional role in HCC cell line Hep3B, in which STMN1
knockdown by siRNA resulted in a 30% decrease in cell viability
(Table 1). The researchers concluded that miR-223 has a role in HCC
through STMN1.
3.5. Ovarian cancer
miR-223 is strongly expressed in ovarian cancer and is the most
upregulated miRNA in recurrent tumors (relative to primary tumors)
[28] (Table 1). Depending on the context, miR-223 acts as either an
oncogene or a tumor suppressor gene; it targets V-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog (KRAS), Epidermal Growth Factor
(EGF) and its receptor Epidermal Growth Factor Receptor 2 (EGFR2)
(which have well characterized roles in ovarian cancer) and also Septin
6 and matrix metallopeptidase 9 (MMP9) (which were found to be
deregulated in a transcriptome study of primary and recurrent ovarian
cancer samples from several different patients).
miR-223 has thus an instrumental role during carcinogenesis in
numerous tissues. It can act as either a tumor suppressor (in leukemia,
hepatocellular carcinoma) or an oncogene function (breast cancer), or
both depending on the clinical context (gastric and ovarian cancers).
4. miR-223 is an inﬂammatory miRNA
4.1. Involvement in inﬂammatory mechanisms
miR-223 regulates the production of nucleotide-binding oligomeri-
zation domain-like receptor protein 3 (NLRP3) and IL-1ß [29]. The
NLRs form the inﬂammosome complex induced by a variety of patho-
gens or cell stresses. NLRP3 is probably the best characterized NLR
and is activated by the presence of toxins, uric acid crystals, amyloid
and other related factors. In turn, this induces IL-1ß processing via
caspase-1 activation. Following stimulation by a Toll-like receptor
ligand, many cell types need the NLRP3 inﬂammosome to initiate an
inﬂammatory response and induce IL-1 ß production. Haneklaus et al.
found that (i) miR-223 targets the NLRP3 3′ UTR, (ii) miR-223 expres-
sion decreases as monocytes differentiate into macrophages and
(iii) NLRP3 protein levels increase. Overexpression of miR-223 prevented
the accumulation of NLRP3 protein and inhibited IL-1 ß production by the
inﬂammosome.
Zhuang et al. [30] demonstrated that miR-223 is involved in the
adipocyte inﬂammation associated with morbid obesity. Indeed, miR-
223−/−mice on a high-fat diet (HFD) displayed more severe systemic
insulin resistance, as demonstrated by a decrease in insulin-induced
adipose tissue Akt phosphorylation, an increase in resistin mRNA levels
and an increase in the insulin response to glucose (despite similar
1005F. Taïbi et al. / Biochimica et Biophysica Acta 1842 (2014) 1001–1009fasting insulin and glucose levels). A marked increase in adipose tissue
inﬂammation was also observed in these mice, including increased
phosphorylation of nuclear factor-κB p65 and enhanced secretion of in-
ﬂammatory mediators (tumor necrosis factor (TNF)-α, IL-1b and IL-6).
When fed an HFD, miR-223−/−mice displayed a high proportion of
pro-inﬂammatory macrophages in adipose cells and stromal cells
(when compared to WT mice) [31]. The speciﬁc role of miR-223 in
regulatory effects in myeloid cell-mediated regulation of adipose tissue
inﬂammation and insulin resistance was conﬁrmed by transplantation
of miR-223−/−myeloid cells into WT recipient mice. The same study
[30] highlighted a role for miR-223 as a novel regulator of macrophage
polarization because it stimulated the alternative anti-inﬂammatory
pathway and suppressed the classic pro-inﬂammatory (IL-1ß/IL-6/
TNF-α) pathways. In this context, miR-223 acted by targeting
PBX/knotted 1 homeobox 1 (Pknox1). Indeed, Pknox1 protein levels
in adipose tissue collected fromHFD-fedmicewere inversely correlated
with miR-223 expression levels. Furthermore, knockdown of Pknox1
in miR-223−/− bone-marrow-derived macrophages (BMDMs) de-
creased pro-inﬂammatory cytokine production. Moreover, Meng et al.
[32] suggested that miR-223 secreted by BMDMs may directly target
adipocytes and modulate their insulin sensitivity. They noted that
plasma miR-223 levels are low in patients with type 2 diabetes [33]
and that insulin-stimulated Akt phosphorylation in adipocytes is
attenuated by co-culture with miR-223-null BMDMs. One can thus
hypothesize that in vivo, the miR-223 secreted by macrophages in
microvesicles regulates metabolic signaling in other tissues.4.2. Involvement in inﬂammatory diseases
4.2.1. Rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease characterized
by inﬂammation of joint synovial tissue and progressive damage to
cartilage and bone tissue (leading to permanent disability in late-stage
disease). Fulci's group [34] demonstrated that miR-223 is upregulated
in T-lymphocytes from RA patients (when compared to those from
healthy donors). The researchers found that miR-223 is predominantly
expressed in CD4+ T helper lymphocytes, which are crucial players in
RA. However, miR-223 levels did not differ signiﬁcantly when compar-
ing patients treated with low-dose corticosteroids and untreated
patients. Furthermore, miR-223 levels were not correlated with RA
severity, age and/or disease duration. As Th17 T helper lymphocytes
were recently shown to have a key role in RA [35], Fulci's group
measured miR-223 expression levels in these cells and found that
they were lower than control naïve CD4+ cells from the peripheral
blood of patients with RA. The predominant expression of miR-223
in CD4+ naïve cells seems to be involved in the etiology of RA
disease. However, little is known about miR-223's exact role(s) in
T-lymphocytes.
Moreover, Li et al. [36] demonstrated that the symptoms of mice
with collagen-induced arthritis (CIA) were alleviated by lentivirus-
mediated miR-223 silencing (LVmiR-223 T). miR-223 is signiﬁcantly
overexpressed in the synovium of RA patients (compared to osteoar-
thritis patients) and the ankle joints of mice with CIA (compared to
normal mice). Treatment with LVmiR-223T reduced osteoclastogenesis
and concomitantly increased levels of NFI-A and macrophage colony-
stimulating factor receptor. The latter is crucial for osteoclastogenesis
and also reduces bone erosion in mice with CIA. Taken as a whole,
these data strongly suggest that miR-223 is involved in the disease
mechanism of RA.
In conclusion, miR-223 acts as an inﬂammatory miRNA, by regulat-
ing the production of the inﬂammosome complex. This miRNA is also
involved in the adipocytic inﬂammation where it is associated with
morbid obesity. Finally, miR-223 is implicated in inﬂammatory diseases
such as RA, by modulating the functions of T helper lymphocytes in
patients.5. MiR-223 in muscles
5.1. miR-223 in cardiac tissues
Lu et al. [37] analyzed 155 miRNAs in left ventricle biopsies from
patients suffering ventricular dysfunction in the presence or absence
of type 2 diabetes. miR-223 was found to be upregulated in these dia-
betic patients. The researchers also observed an increase in glucose up-
take by rat cardiomyocytes transfected with miR-223. In transfection
experiments, over-expression of miR-223 in cardiomyocytes induced
an increase in GLUT-4 expression, which was necessary and sufﬁcient
for increasing glucose uptake by these cells. This relationship was con-
ﬁrmed by transfection of murine left ventricle cardiomyocytes with
anti-mmu-miR-223, which induced a decrease in GLUT-4 expression
(relative to matched controls). Greco et al. [38] showed that miR-223
is differently expressed in diabetic patients with heart failure (D-HF)
or matched non-diabetic patients with heart failure (ND-HF). miR-223
levels were abnormally low in both groups, although the decrease was
less marked in D-HF patients than in ND-HF patients. Moreover, this
decrease was attenuated in the distant zone in D-HF patients and the
border zone in ND-HF patients. The researchers hypothesized that the
observed, diabetes-associated induction ofmiR-223 [37]might counter-
act the decrease inmiR-223 levels provoked by other stimuli. In support
of this hypothesis, it had been previously reported [39] that miR-223
levels are elevated in end-stage ischemic cardiomyopathy. One could
thus hypothesize that the decrease in miR-223 is an adaptive mecha-
nism that is active in early-stage patients but lost in end-stage patients.
5.2. An emerging role for miR-223 in vascular damage, including
atherosclerosis
De Rosa et al. [40] measured concentration gradients of several
miRNAs throughout the coronary circulation, with a focus on miR-223
(which is known to be an enriched miRNA in platelets). Plasma was
simultaneously obtained from the aorta and coronary venous sinus of
patients with stable coronary artery disease (CAD) or troponin-positive
acute coronary syndrome (ACS). Aortic plasma levels of miR-223 were
higher (although not signiﬁcantly) in patients with ACS than in patients
with CAD, whereas there was no difference between the two groups for
samples from the coronary sinus. To distinguish between heart-speciﬁc
and systemic alterations in circulating miRNA levels, they calculated the
transcoronary concentration gradients by subtracting plasma miRNA
levels in the aorta from the levels in the coronary sinus. There was no
signiﬁcant intergroup difference in miR-223 concentrations, although a
trend towards a decrease in levels during transcoronary passage was
identiﬁed.
Song et al. [41] used a microarray analysis of RNA isolated from
vascular smoothmuscle cells (VSMCs) cultured under dynamic or static
conditions to demonstrate that miR-223 is downregulated under
stretch stress. A qPCR experiment showed that miR-223 levels were
four-fold lower under stretch stress conditions than under static condi-
tions. Overexpression of miR-223 (via retroviral infection of VSMCs)
decreased protein levels of IGF-1R (which are elevated after 24 h of
exposure to stretch stress). Inhibition of IGF-1R production (using
siRNA) and PI3K respectively prevented and signiﬁcantly decreased
the stretch stress-enhanced proliferation of VSMCs. Hence, stretch
stress was found to induce VSMC proliferation via an increase in IGF-
1R functionality and downstream PI3K–Akt signaling. Lastly, overex-
pression of miR-223 in VSMCs inhibited stretch-stress-enhanced
proliferation and prevented the activation of PI3K–Akt signaling. In
conclusion, the downregulation of miR-223 induced by stretch stress
contributes to VSMC proliferation by enhancing the activity of IGF-1R
and its downstream PI3K–Akt signaling.
Kin et al. [42] studied tissue- and plasma-speciﬁc microRNA
signatures for atherosclerotic abdominal aortic aneurysm (AAA). Tissue
wall samples from patients undergoing AAA repair and patients
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microRNA arrays and RT-PCR assays. miR-223 was found to be signiﬁ-
cantly upregulated in AAA tissue, and there was a signiﬁcant negative
correlation between monocyte chemoattractant protein-1 and TNF-α
expression levels on one hand and miR-223 expression levels on the
other. Interestingly, plasma miR-223 levels were low in patients with
AAA.Fig. 3. A. mir-223 is a biomarker of Chronic Kidney Disease (CKD), atherosclerosis and vascul
Chronic Kidney Disease (CKD), atherosclerosis and vascular calciﬁcation. In the presence of an in
smooth muscle cells (VSMCs) transdifferentiate into a synthetic phenotype, reﬂective of a path
miR-223 is increased in the aorta and conversely, the expression of this miRNA decreases in the
miR-223 levels. B. At the early stage of atherosclerosis, macrophages are recruited in the ather
erosclerosis. In the atherome plaque we propose that they could interact with endothelial cell
cells. miR-223 could as a consequence modulate in these cells a phenotypic switch towards deIn our laboratory, Rangrez et al. [43] demonstrated that miR-223 is
expressed in VSMCs and is signiﬁcantly upregulated in vitro in the pres-
ence of inorganic phosphate (Pi, a well-known calcifying uremic toxin).
Over-expression ofmiR-223 in VSMCs in our static conditions increased
cell proliferation and migration. In the same conditions we observed
elevated levels of miR-223 and concomitantly low expression of two
miR-223 targets (Mef2c and RhoB). Interestingly, we also found thatar calciﬁcation. Recapitulative representation of miR-223 relevance in murine models of
ﬂammatory context in CKD, atherosclerosis and vascular calciﬁcation, contractile vascular
ogenic context, and endothelial cells become dysfunctional. In this inﬂammatory context,
serum. Sevelamer treatment alleviates symptoms of CKD and reestablishes at least partly
omatous plaque by diapedesis and are converted into foam cells at the later stages of ath-
s and vascular smooth muscle cells using gap junctions to transfer miR-223 into recipient
differentiated/proliferative states.
1007F. Taïbi et al. / Biochimica et Biophysica Acta 1842 (2014) 1001–1009miR-223 is upregulated in aorta samples collected fromApoE knock-out
mice, which display vascular calciﬁcation— amajor risk factor in kidney
disease and subsequent vascular complications. Indeed, patients in the
later stages of chronic renal disease (CKD) develop vascular calciﬁca-
tion, which is associated with higher cardiovascular morbimortality
[44]. The scarce literature data suggest that miRNAs are involved in
the physiopathology of CKD, since they are important regulators of
VSMC and endothelial cell plasticity. In studies of murine models of
CKD and atherosclerosis, we recently reported that miR-223 is
deregulated in atherosclerotic aortas, which develop vascular calciﬁca-
tions [45]. Our data in mice demonstrate that miR-223 can be detected
in normal, uremic and atherosclerotic aortas. Importantly, levels ofmiR-
223 and its targets GLUT-4 andNFIA are altered during the crucial stages
of CKD and atherosclerosis (Table 1 and Fig. 3A). miR-223 levels were
found to be correlated with classical biomarkers of CKD and atheroscle-
rosis, such as cholesterol, urea and calcium levels. Furthermore, the
observation that the calcium-free phosphate-binding drug sevelamer-
carbonate alleviatesmiRNA deregulation suggests a direct link between
miRNA alterations and CKD/atherosclerosis. Until very recently, it
was considered that miR-223 was not present in endothelial cells [46].
However, Fleming's group [47] has shown that miR-223 is strongly
expressed in endothelial cells but can only be detected in freshly
isolated cells. The authors claim that miR-223 mainly acts by targeting
integrin-beta 1 (a transmembrane receptor involved in cell–cell and
cell–matrix interactions and communication) and by preventing
growth factor signaling. Interestingly, Fleming's group also observed in-
creases in arteriogenesis in ischemic muscles and endothelial sprouting
in aortic rings in miR-223−/− mice. These results strongly argue in
favor of an endothelial role for miR-223 (along with its role in VSMCs
[43]) in vasculogenesis.
We also quantiﬁed serum miR-223 levels in our murine models
after two and ten weeks of exposure to CKD (see [45] and Fig. 3A).
Two weeks after the induction of CKD, serum miR-223 levels were sig-
niﬁcantly lower in Apo-E KOmice than inWT counterparts. This clearly
suggests that miR-223 is a potential early biomarker for atherosclerotic
damage. Serum miR-223 levels were also low after ten weeks of CKD.
Lastly, at that stage of the disease, levels of miR-223 were lower in
serum from CKDmice than from sham-operated mice, while the oppo-
site was true for aortic samples. As mentioned above, a serum vs. tissue
difference in miR-223 expression levels was also found in patients
undergoing AAA repair [42]. Serum levels of miR-223 were also found
to be inversely associated with disease severity in patients with type 2
diabetes [33], who often suffer from vascular calciﬁcation and athero-
sclerosis [48]. Taken as a whole, these recent data suggest that miR-
223may be a valuable, independent, noninvasive biomarker in patients
with CKD, atherosclerotic and/or type 2 diabetes patients. In addition,
we propose that miR-223 deregulation could contribute to the develop-
ment ofmetabolic and vascular disorders in CKDpatients bymodulating
GLUT-4 expression, and thus glucose uptake which will in turn induce
the insulin resistance common in these disorders [49]. In this respect,
it is interesting that miR-223 was also found to be upregulated in
diabetic patients [32], the number one cause of CKD. Also, since inﬂam-
mation is prevalent in the pathophysiology of CKD [44], the increase of
the inﬂammation-regulated miR-223 [29] we found in CKD could be a
consequence of this. In this regard, Bao et al., when studying renal inju-
ries in IgA nephropathy published that miR-223 was able to inhibit cell
proliferation and alleviate the inﬂammatory status in endothelial cells
[50]. Since it was already demonstrated that miR-223 can transfer
from human macrophages to hepato-carcinoma cells and inhibit their
proliferation [16], one can hypothesize that, in CKD and atherosclerosis,
miR-223 transfers frommonocytes and spumous macrophages present
in atheromatous and vascular calciﬁed lesions to vascular smooth
muscle cells from the media and/or endothelial cells from the intima.
Mir-223 could thus play a pivotal role in the modulation of the
phenotype of these cells, and consequently of the vascular calciﬁcation
processes (Fig. 3B).Furthermore, miR-223 was recently described as a regulator of
cholesterol uptake [51]. In fact, miR-223 targets the scavenger receptor
class B, type I (SR-BI), the levels of which are low in diabetic mice.
Hence, miR-223 may be a potential biomarker for the intracellular
trafﬁcking of cholesterol and may thus constitute a novel drug target
for normalizing this trafﬁcking (notably in atherosclerotic disease).
5.3. miR-223 in skeletal muscular dystrophy
Greco et al. [52] studied the miRNAs involved in skeletal muscle
damage and regeneration during the course of Duchenne muscular
dystrophy (DMD). They found that 11 miRNAs (including miR-223)
were deregulated in bothmdxmice (a murine genetic model of DMD)
and DMD patients and referred to this set as the DMD signature. The
expression of miR-223 in areas of damaged muscle is correlated with
the presence of inﬁltrating inﬂammatory cells and myoﬁbril necrosis/
regeneration — all of which are hallmarks of DMD patients and mdx
mice. Using a murine model of acute ischemia (the 129 SvEv strain) in
which femoral arterywas removed to induce a rapid increase in apopto-
sis and necrosis throughout the muscle followed by a regeneration
phase, Greco et al. observed that expression ofmiR-223was strongly in-
duced in the two days following ischemia and then declined over time.
The areas of damagedmuscle contained not only necrotic and apoptotic
myoﬁbrils but also inﬁltrating inﬂammatory cells. miR-223 was strongly
induced in the damagedmyoﬁbrils. As expected, miR-223was not mod-
ulated in the skeletal muscle of newborn mice because of the absence of
inﬂammation during normal growth. Moreover, Chen et al. [53] also
showed that miR-223 levels increased immediately after cardiotoxin in-
jury of the murine tibialis anterior muscle.
Several studies show thus a clear trend towards an upregulation of
miR-223 in various clinical disorders associated with cardiac, smooth
and skeletal muscle cells. This is particularly obvious in the cardiac
tissue from diabetic patients, in the smooth muscle cells from athero-
sclerotic tissue, and in the skeletal muscle from DMD. Further work
will clearly be needed to determine if the molecular mechanisms
implicated in the physiopathology of these various muscle cell types
are identical or not.
6. miR-223 is a promising, non-invasive biomarker in cancer and
cardiovascular disease
Due to the complexity of disease processes, novel predictive factors
are becoming increasingly useful for diagnosis. Over the last decade,
miRNAs have emerged as potential biomarkers of many diseases
(including cardiovascular disorders).Mitchell et al. [54]ﬁrst demonstrat-
ed the presence of circulating miRNAs in human plasma. These miRNAs
are transported by microvesicles (which protect their cargo against
RNase activity [55]) or as a complex with the chaperon argonaute 2
and/or lipoproteins. Marsh's group found that (i) macrophage-derived
microvesicles contain miRNAs (including miR-223), (ii) these vesicles
were transported to target cells (including endothelial cells, monocytes
and ﬁbroblasts) and (iii) miR-223 was functionally active in the target
cells [15]. In contrast, Arroyo's group found that non-vesicular miR-223
was associated with an argonaute2-containing ribonucleoprotein com-
plex [56]. Resolution of this discrepancy will require further research.
Several studies have demonstrated a correlation between plasma
miRNA levels and diseases such as cancer [57] — thus highlighting the
miRNAs' potential roles as non-invasive biomarkers [58]. Stephanie
Dimmeler's group was the ﬁrst to show that serum miRNA levels are
altered in the serum of patients with CAD (relative to healthy counter-
parts) [59].
In studies of cardiovascular disease, endogenous, circulatingmiRNAs
(e.g.miR-454, U6 andmiR-17-5p) have been used to normalize circulat-
ing serum miRNA levels. However, the use of spiked-in, exogenous
non-human miRNA (e.g. synthetic Caenorhabditis elegans miR-39) is
increasingly common, as no additional experimental bias is added
1008 F. Taïbi et al. / Biochimica et Biophysica Acta 1842 (2014) 1001–1009[54]. Lastly, other body ﬂuids may be suitable for diagnosis, since it was
recently shown that miR-223 and other miRNAs can be detected in
human saliva [60].
7. Conclusions/perspectives
Given the abundant, recent literature, it is now increasingly clear
that miR-223 is involved in the regulation of a broad range of important
cellular processes (including cell cycle regulation) and the invasiveness
of many different cell types, hematopoietic differentiation and immune
cell function. The role of miR-223 in the cardiovascular system is
becoming increasingly clear and we have described its involvement in
metabolism-related disorders such as diabetes, obesity-induced inﬂam-
mation and cholesterol transport. Serum and tissue levels of miR-223
are becoming useful clinical parameters. The next challenge will now
be to therapeutically modulate levels of this miRNA and relieve symp-
toms in animal models and then patients.
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